Luzu (luliconazole) / Bausch Health - LARVOL DELTA

Consensus recommendations for Trichophyton indotineae: A modified Delphi study. (PubMed, J Eur Acad Dermatol Venereol) - "These consensus statements provide practical interim recommendations. Randomized controlled trials are needed to validate outcomes and optimize regimens."

Journal • Dermatology • Infectious Disease

Dematiaceous fungal keratitis: prevalence, spectrum, clinical features, outcome, and antifungal susceptibility from a tertiary care centre in North India. (PubMed, Med Mycol) - "Antifungal susceptibility testing (AFST) was performed as per the CLSI (Clinical Laboratory and Standards Institute) broth microdilution method (M38-A2) for a panel of 9 drugs including voriconazole, itraconazole, posaconazole, luliconazole, miconazole, ketoconazole, amphotericin-B, natamycin and terbinafine. as the predominant causative agent. In vitro susceptibility of voriconazole demonstrated better performance against DFK isolates."

Journal • Infectious Disease • Keratitis • Ocular Inflammation • Ophthalmology

Comparative Evaluation of the Antifungal Effect of Blue Light and Luliconazole in an Animal Model of Dermatophytosis (EADV 2026) - No abstract available

Preclinical • Dermatology

Inflammatory-Type Tinea Corporis from Trichophyton mentagrophytes Animal Type 3 with Suspected Infection from a Guinea Pig. (PubMed, Med Mycol J) - "The isolated fungus was morphologically identified as belonging to the Trichophyton mentagrophytes complex, and topical luliconazole cream was administered...These findings strongly suggested zoonotic transmission from the pet guinea pigs. This appears to be one of the very few reported cases of T. mentagrophytes animal type 3 isolated from a human lesion."

Journal • Dermatology • Infectious Disease

Equine Fungal Keratitis due to Cladorrhinum bulbillosum. (PubMed, Vet Ophthalmol) - "C. bulbillosum infection caused equine fungal keratitis in this case. The use of topical voriconazole and luliconazole, combined with surgical intervention (keratectomy, cryotherapy, bio scaffold graft), resulted in a good response. The corneal ulcer healed well with minor scarring over 8 weeks following surgical intervention. To the authors' knowledge, this was the second report of equine fungal keratitis caused by C. bulbillosum. This case highlights the utility of next-generation DNA sequencing and multimodal treatment with adjunctive contemporary therapies."

Journal • Anesthesia • Infectious Disease • Keratitis • Ocular Inflammation • Ophthalmology

Morphological Changes in Fungal Elements and Antifungal Drug Susceptibility in an Ex Vivo Model of Fungal Keratitis. (PubMed, Invest Ophthalmol Vis Sci) - "An ex vivo fungal keratitis model was developed using porcine corneas, which were inoculated with F. solani and assigned to four treatment groups: natamycin (NAT), voriconazole (VRCZ), luliconazole (LLCZ), or saline (uninfected control). The LLCZ-treated group not only suppressed fungal growth but also caused structural disruption of fungal cells after additional administration, suggesting a strong antifungal effect. We successfully established an ex vivo Fusarium keratitis model using porcine corneas, which enabled us to evaluate antifungal susceptibility by quantifying fungal growth and observing fungal morphological changes."

Journal • Preclinical • Infectious Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Wide-Range Quantification of Belumosudil in Patients with Chronic Graft-Versus-Host Disease by High-Performance Liquid Chromatography. (PubMed, Ther Drug Monit) - "This study presents the first development and validation of a simple, novel, and broad-range high-performance liquid chromatography-ultraviolet approach for quantifying plasma belumosudil, supporting its suitability for therapeutic drug monitoring in clinical practice."

Journal • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

Microbiological Spectrum, risk factors, and antifungal susceptibility of fungal keratitis in the Indore region of Central India. (PubMed, Indian J Ophthalmol) - "Fusarium spp. and Aspergillus spp. causing FK is a major concern in the Indore region. Triazoles exhibit superior in vitro antifungal activity against common FK pathogens, especially Aspergillus flavus and Fusarium spp."

Journal • Keratitis • Mood Disorders • Ocular Inflammation • Ophthalmology

Luliconazole Potentiates Efficacy of Miltefosine Against Leishmania donovani. (PubMed, Drug Dev Res) - "Further investigations including formulation development and in vivo validation, are needed to assess the translational potential. This is the first study to demonstrate that luliconazole enhances miltefosine efficacy against L. donovani."

Journal • Infectious Disease

Efficacy Evaluation of Luliconazole-Loaded Nanostructured Lipid Carriers in Treatment-Resistant Dermatophytosis: A Randomized Clinical Trial. (PubMed, Mycoses) - "These findings indicate that NLC-LCZ enhanced antifungal efficacy and quality of life in TRB-resistant dermatophytosis, and that combination therapy with ITZ + NLC-LCZ yielded the highest recovery, representing a promising strategy against resistant infections."

Clinical • Journal • Dermatology • Infectious Disease • Inflammation

Tinea Cruris and Pedis Caused by Terbinafine-Resistant Trichophyton rubrum Treated with Luliconazole. (PubMed, Med Mycol J) - No abstract available

Journal • Dermatology

Clinical Management of Antifungal-Resistant Dermatophytosis in Japan. (PubMed, Med Mycol J) - "For suspected terbinafine-resistant infections, non-SQLE azoles, such as luliconazole and lanoconazole, are recommended because of their 10- to 100-fold increased activity against Trichophyton species. Oral fosravuconazole and topical agents such as 10% efinaconazole or 5% luliconazole have proven effective for onychomycosis. Ongoing surveillance, appropriate antifungal stewardship, and timely adjustment of treatment regimens are essential to prevent the further spread of antifungal-resistant dermatophytosis."

Journal • Review • Dermatology • Infectious Disease • SQLE

Interdigital Tinea Pedis Caused by Terbinafine-Resistant Trichophyton rubrum Treated with Luliconazole. (PubMed, Med Mycol J) - No abstract available

Journal • Dermatology • Infectious Disease

Baseline Nail Thickness and Great Toenail Involvement Are Associated With Poor Response to Topical Antifungal Therapy for Onychomycosis: A Lesion-Level Generalized Estimating Equations Analysis. (PubMed, J Dermatol) - "We retrospectively studied patients with onychomycosis treated with topical luliconazole 5% nail solution or efinaconazole 10% solution between 2017 and 2021. Sensitivity analyses using a linear mixed-effects model showed consistent directions of effect. Great toenail involvement appears to be a robust predictor of poor response to topical therapy, and increased nail thickness may particularly hinder achieving complete cure; these findings warrant cautious interpretation given the retrospective, non-randomized design."

Journal • Infectious Disease

Erythrokeratoderma Variabilis With Persistent Facial Involvement, An Affected Sibling And Secondary Dermatophyte Infection (EADV-Sp 2026) - "The patient was treated with topical luliconazole for dermatophyte infection and systemic acitretin (25 mg/day) with topical calcipotriol/betamethasone for EKV, and was placed under regular clinical follow-up. Secondary dermatophyte infection may obscure the underlying genodermatosis and complicate diagnosis. Integrated clinical, histopathological and mycological assessment enables accurate diagnosis and appropriate combined antifungal and systemic therapy in EKV."

Infectious Disease

Dual CARD9/GATA2 Mutations Promote Refractory Neoscytalidium dimidiatum Subcutaneous Infection: Synergistic Clearance by Voriconazole and Targeted Hyperthermia (AAD 2026) - "Initial oral itraconazole treatment (200-400 mg/d) showed transient improvement over 3 months but resulted in relapse with drug resistance after discontinuation...Successful management involved voriconazole (400 mg/d) combined with luliconazole cream and localized hyperthermia (42°C/d) based on antifungal susceptibility testing (MIC 0.06 μg/ml) and thermotolerance data showing no growth at 42°C, achieving significant lesion regression within 8 weeks without recurrence during follow-up. Notably, dermoscopic examination identified a "black-red dot sign" on erythematous bases with yellowish scales that resolved alongside clinical improvement, suggesting potential as a fungal subcutaneous infection biomarker. This case highlights CARD9/GATA2 mutations as possible contributors to chronic fungal infections and drug resistance mechanisms in immunocompetent individuals while demonstrating the therapeutic value of combined antifungal and thermotherapy..."

Cardiovascular • Hypertension • Infectious Disease • Inflammation • CARD9 • GATA2

Hydrogen-bonding functionalities of selected azole drugs in multicomponent crystals with trithiocyanuric acid. (PubMed, Acta Crystallogr C Struct Chem) - "The azole APIs include imidazole-derived econazole and luliconazole, as well as 1,2,4-triazole-derived isavuconazole, voriconazole and posaconazole, and the crystalline forms reported are econazolium trithiocyanurate, C18H16Cl3N2O+·C3H2N3S3-, luliconazole-trithiocyanuric acid (1/1), C14H9Cl2N3S2·C3H3N3S3, isavuconazole-trithiocyanuric acid (1/1), C22H17F2N5OS·C3H3N3S3, voriconazole-trithiocyanuric acid-water (1/2/3), C16H14F3N5O·2C3H3N3S3·3H2O, and posaconazole-trithiocyanuric acid (1/1), C37H42F2N8O4·C3H3N3S3. To elucidate the nature of these key interactions, a QTAIM analysis was performed and pairwise interaction energies were evaluated to clarify the stability and energetics of the resulting assemblies. The influence of chiral azole molecules, their specific hydrogen-bond functionalities and the solvation conditions on the formation of the supramolecular motifs is also discussed."

Journal

Formulation Design Using Ionic Liquids to Enhance Luliconazole Topical Efficacy Against Superficial Candida Albicans Mycosis. (PubMed, Ann Pharm Fr) - "It also demonstrated superior antifungal activity against Candida albicans compared to that of marketed formulations. The improved permeation and antifungal activity of LCZ-IL-gel indicate its strong potential for clinical translation as a more effective topical therapy for superficial fungal infections."

Journal • Dermatology • Infectious Disease

Potential therapeutic role of luliconazole against azole-resistant invasive aspergillosis in a murine model (ESCMID Global 2026) - No abstract available

Preclinical • Respiratory Diseases

Optimized polymeric micellar In situ gel formulation incorporating luliconazole for targeted management of fungal endophthalmitis: In vitro characterization, ex vivo ocular permeation, and in vivo ocular irritation evaluation. (PubMed, Exp Eye Res) - "Antifungal studies indicated significant efficacy against pathogenic fungi, while in vivo ocular irritation tests in rabbits showed good tolerance. In conclusion, the obtained results suggested that developed polymeric micellar in situ gel can serve as a promising drug delivery system to enhance LCZ ocular antifungal activity."

Journal • Preclinical • Ocular Infections • Ocular Inflammation • Ophthalmology

SeDeM and Powder flow tools-assisted design of solid SMEDDS of luliconazole for antifungal therapy. (PubMed, Ther Deliv) - "The solid SMEDDS powders became free flowing, showing enhanced ex vivo drug release (39% wheat straw, 29.74% Neusilin® US2, n = 3) and improved transdermal permeation (47.89% and 45.27%, n = 3), with strong antifungal activity against Candida albicans (zones of inhibition: 22 ± 1 mm and 20 ± 1.2 mm) but limited effect on Aspergillus niger. The S-SMEDDS platform enhanced luliconazole solubility, transdermal delivery, and stability, offering a safe, effective, and scalable topical formulation for fungal infections and a practical route for industrial-scale production."

Journal • Infectious Disease

Formulation and evaluation of a dual-drug film-forming topical gel for synergistic antifungal therapy against cutaneous candidiasis. (PubMed, J Pharm Sci) - "In this work, a chitosan-based film-forming gel (FFG) was developed incorporating luliconazole (LUL) and carvacrol (CAR) to improve dermal delivery and therapeutic performance...Safety was confirmed through skin irritation and histopathological evaluations, and stability analysis demonstrated robustness for six months. These findings establish CAR-LUL FFG as a promising topical platform for effective management of resistant Candida infections."

Journal • Candidiasis • Infectious Disease

Enhanced antifungal therapy for cutaneous candidiasis: Development, evaluation, and optimization of luliconazole-loaded transethosomal gel. (PubMed, J Pharm Sci) - "In vivo studies in a Candida-infected rat model showed a 1.50-fold reduction in treatment duration with the LCZ-TEG formulation. These findings suggest that the developed LCZ-TEG significantly improves the solubility, skin penetration, and antifungal efficacy of luliconazole, supporting its potential as a promising, efficient, and targeted therapy for Cutaneous Candidiasis."

Journal • Candidiasis • Dermatology • Infectious Disease

P versicolor: Comparison of the Efficacy of Topical Luliconazole 2% Cream vs Topical Ketoconazole 1% Cream in the Treatment of Pityriasis Versicolor. (clinicaltrials.gov) - P4 | N=86 | Not yet recruiting | Sponsor: PAEC General Hospital, Islamabad

New P4 trial

Luliconazole-Loaded Nanoliposomes as a Repurposing Strategy to Combat Memory Dysfunction in LPS-Induced Alzheimer's Rats. (PubMed, ACS Omega) - "The histopathological observation of brain tissue in the LuNLs/control group further substantiated the in vivo behavioral study data. Based on the reports, luliconazole may be used as a viable, efficacious alternative for the treatment of AD, though further preclinical studies are highly warranted."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Infectious Disease